Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and.

Slides:

Advertisements

Similar presentations

500X 1000X Name the organ from which these slides were prepared.

Advertisements

GRADING OF REJECTION IN PANCREAS ALLOGRAFTS Are changes needed? Cinthia B. Drachenberg, M.D. University of Maryland School of Medicine Baltimore MD.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.

(Copyright © 1977 American Diabetes Association. Marliss EB et al

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

Insulin content of isolated pancreas and islet morphology.

Volume 136, Issue 2, Pages (February 2009)

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Immunohistochemical analysis.

Antitumor effects of FF and gemcitabine on two pancreatic PDX models.

Loss of DGKζ and Cbl-b results in a greater percentage of splenic CD8+ T cells with an activated phenotype. Loss of DGKζ and Cbl-b results in a greater.

mpJX-594 effects on tumor burden and leukocyte influx.

Islet mass and β-cell proliferation is decreased in Hhip–/– embryos (Hip1 in figure). Islet mass and β-cell proliferation is decreased in Hhip–/– embryos.

Expression of the neural stem cell–specific marker nestin in a distinct cell population within pancreatic islets. Expression of the neural stem cell–specific.

Transcription factor network of human pancreas development.

WASH cKO mice display a normal pancreatic development.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Sources of new β-cells. 1. Sources of new β-cells. 1. Proliferation of β-cells, which requires specific cyclins, cyclin-dependent kinases (cdk), and the.

α-Cells mainly express SSTR2 and SSTR3

Pancreatic β-cell proliferation.

Human and mouse islets express MCH and MCHR1.

Percentage of Florida adults with diagnosed diabetes who received services or engaged in self-management practices by DSME duration category, Florida BRFSS.

Fragment N expression does not affect islet morphology and cellularity

Grg3 works with Pdx1 to repress α-cell genes and induce glucose-stimulated insulin secretion. Grg3 works with Pdx1 to repress α-cell genes and induce glucose-stimulated.

Plasma levels of GLP-1 are increased in patients with critical illness and correlate with disease severity. Plasma levels of GLP-1 are increased in patients.

T2D loci stratified by patterns of quantitative trait (e. g

Grg3 is expressed in most β-cells but less frequently in α-cells.

Insulin levels are increased in the MBH of Ugcgf/f//CamKCreERT2 mice.

Somatostatin released by δ-cells exerts a tonic inhibition on glucagon and insulin secretion but is not required for the glucagonostatic effect of glucose.

A-N: Immunofluorescence analysis of Bcl family genes in human islets of Langerhans. A-N: Immunofluorescence analysis of Bcl family genes in human islets.

Uptake of [11C]5-HTP in the human pancreas is not dependent on perfusion. Uptake of [11C]5-HTP in the human pancreas is not dependent on perfusion. A:

T1D is reduced in CT-treated NOD mice.

Insulitis is reduced in CT-treated RIP-LCMV-GP mice.

E11 pancreas cultured for 6 days in the presence of morpholine-ring antisense against GIP, GIPR, or control. E11 pancreas cultured for 6 days in the presence.

Expression of IRS2 ameliorates the effects of ATF3 in cultured β-cells

Chop deletion preserves β-cell function in P58IPK−/− mice.

Supplementation of c-Rel–competent Treg cells reverts exacerbated diabetes in c-Rel−/− NOD mice. Supplementation of c-Rel–competent Treg cells reverts.

VIP treatment decreased the number of apoptotic cells and increased cell proliferation. VIP treatment decreased the number of apoptotic cells and increased.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Oxidative stress, superoxide, and Pdx-1 levels in pancreatic islets of diabetic mice. Oxidative stress, superoxide, and Pdx-1 levels in pancreatic islets.

PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded skin. PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded.

MANF expression is required for maintaining β-cell mass.

Expression of VPAC2 in the pancreas at E13.

Correlation between pancreatic 111In-exendin accumulation and BCM

Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,

Homing and proliferation of antigen-specific T-cell (A) CFSE staining of polyclonal (CD4), GAD p286–specific (GAD), and BDC2.5 cells in pancreatic lymph.

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control hamster Ig–and.

Expression of PKCδ in islets and other tissues of control and PKCδKN-overexpressing mice. Expression of PKCδ in islets and other tissues of control and.

Increased pancreatic insulin content and islet size and protection against HFD- and palmitate-induced cell death in PKCδKN-overexpressing mice. Increased.

Apoptosis in CAM vessels after staining with TUNEL

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

IL-1R deficiency does not protect syngeneic grafts from destruction.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Transaxial sections of contrast-enhanced MRI showing the body and tail of the pancreas (A and B). Transaxial sections of contrast-enhanced MRI showing.

RBP4 and glucose metabolism.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

TSA-mediated changes in cell cycle inhibitor proteins.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Plots of average estimated and measured GFR vs

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Postoperative blood glucose levels and total insulin requirement.

Coincidence and prognostic significance of PD-1+ and CD103+ cells in HGSC. Serial sections from the 490-case TMA were stained with antibodies to CD103.

Presentation transcript:

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and those with chronic pancreatitis. Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and those with chronic pancreatitis. Each point represents an individual patient and is usually the mean of several sections analyzed. All ducts on each section were counted (on average ∼100 ducts per patient). There are significant differences between these two groups for glucagon (P < 0.005), amylase (P < 0.0003), Ki67 (P < 0.0005), PDX-1 (P < 0.0005), and insulin (P < 0.05). Jenny M. Phillips et al. Diabetes 2007;56:634-640 ©2007 by American Diabetes Association